EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 3.0

Effects of Pemafibrate on Cardio-Ankle Vascular Index (CAVI) in Patients with Type 2 Diabetes or Ischemic Heart Disease: A 24-Week Observational Study

Yasuhiro Watanabe iD, Shoya Nonaka, Shuhei Yamaoka, Shoko Nakamura, Osamu Horikawa iD, Takashi Yamaguchi, Shuji Sato iD, Shunsuke Todani, Yuta Sugizaki, Takuro Ito, Hiroshi Mikamo, Mao Takahashi iD und 3 weitere

Vascular Health and Risk Management · 2025

DOI: 10.2147/vhrm.s506642 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Vascular Health and Risk Management, 2025. Verfasst von Yasuhiro Watanabe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center, Chiba, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Vascular Stiffness, Benzoxazoles, Myocardial Ischemia. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Vascular StiffnessBenzoxazolesMyocardial IschemiaButyratesCardio Ankle Vascular IndexHypolipidemic AgentsHumansMaleFemaleMiddle AgedProspective StudiesAgedBiomarkersTime FactorsTreatment OutcomeLipidsPPAR alphaPredictive Value of Tests

Stichwörter der Autor:innen

CAVIcardio-ankle vascular indexhypertriglyceridemiapemafibratetype 2 diabetes mellitus

Substanzen

(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidBiomarkersBenzoxazolesButyratesHypolipidemic AgentsLipidsPPAR alphaPPARA protein, human

Autor:innen und Institutionen

  • Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center, Chiba, Japan.
  • Division of Cardiology, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan.
  • Nagayama Clinic, Tochigi, Japan.

ORCID-Profile: Yasuhiro Watanabe, Osamu Horikawa, Shuji Sato, Mao Takahashi, Daiji Nagayama, Kazuhiro Shimizu

Zitieren

APA

Watanabe, Y., Nonaka, S., Yamaoka, S., Nakamura, S., Horikawa, O., Yamaguchi, T., Sato, S., Todani, S., Sugizaki, Y., Ito, T., Mikamo, H., Takahashi, M., Nagayama, D., Shimizu, K., & Saiki, A. (2025). Effects of Pemafibrate on Cardio-Ankle Vascular Index (CAVI) in Patients with Type 2 Diabetes or Ischemic Heart Disease: A 24-Week Observational Study. Vascular Health and Risk Management. https://doi.org/10.2147/vhrm.s506642

Vancouver

Watanabe Y, Nonaka S, Yamaoka S, Nakamura S, Horikawa O, Yamaguchi T, et al. Effects of Pemafibrate on Cardio-Ankle Vascular Index (CAVI) in Patients with Type 2 Diabetes or Ischemic Heart Disease: A 24-Week Observational Study. Vascular Health and Risk Management. 2025. doi:10.2147/vhrm.s506642

BibTeX
@article{Watanabe2025,
  author = {Watanabe, Yasuhiro and Nonaka, Shoya and Yamaoka, Shuhei and Nakamura, Shoko and Horikawa, Osamu and Yamaguchi, Takashi and Sato, Shuji and Todani, Shunsuke and Sugizaki, Yuta and Ito, Takuro and Mikamo, Hiroshi and Takahashi, Mao and Nagayama, Daiji and Shimizu, Kazuhiro and Saiki, Atsuhito},
  title = {Effects of Pemafibrate on Cardio-Ankle Vascular Index (CAVI) in Patients with Type 2 Diabetes or Ischemic Heart Disease: A 24-Week Observational Study},
  journal = {Vascular Health and Risk Management},
  year = {2025},
  doi = {10.2147/vhrm.s506642}
}
Kostenlos starten →